Quick answer
KPV is the C-terminal tripeptide (residues 11–13) of alpha-MSH, but it lacks the His-Phe-Arg-Trp core that engages melanocortin receptors, so the two are not interchangeable tools.
- Size: KPV 3 residues (~342 Da); alpha-MSH 13 residues (~1,665 Da)
- Receptors: alpha-MSH binds MC1R/3R/4R/5R; KPV binds weakly or not at all in most reports
- Transport: KPV is a PepT1 substrate; alpha-MSH is not
- Design: use alpha-MSH as the receptor-engaging arm and KPV to isolate receptor-independent signal
- Products: KPV vial, GHK-Cu + KPV, CoA library
For laboratory research use only; not for human consumption.
Why the two are compared
KPV and alpha-MSH are discussed together in melanocortin-pathway research because KPV is the C-terminal tripeptide of the larger alpha-MSH sequence. They share a research lineage: both have been studied in inflammatory-signaling models, and both intersect with melanocortin biology. They are nonetheless distinct tools with different structures and, in most accounts, different upstream mechanisms. Treating them as interchangeable in a study design is a common source of confusion, and this article sets out where they overlap and where they do not. Background on KPV alone is in the KPV research overview and what is KPV.
Everything described here is research-model evidence. Neither peptide is an approved product for the uses discussed, and findings from cell lines and animal models should not be extended beyond those systems.
Structural relationship
Alpha-MSH is a 13-residue peptide, Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2, cleaved from the pro-opiomelanocortin (POMC) precursor. The N-terminus is acetylated and the C-terminus is amidated, modifications that are part of the natural hormone. KPV corresponds to residues 11–13: lysine, proline, valine. In structure-activity work on the parent molecule it is among the smallest fragments that retains anti-inflammatory activity.
| Property | Alpha-MSH | KPV |
|---|---|---|
| Length | 13 residues | 3 residues |
| Approximate mass | About 1,665 Da | About 342 Da (free tripeptide) |
| Source | POMC precursor | C-terminal fragment (residues 11–13) of alpha-MSH |
| Contains His-Phe-Arg-Trp core | Yes (residues 6–9) | No |
| Terminal modifications | N-acetyl, C-amide | Depends on the supplied form; check the CoA |
The difference in size has practical and mechanistic consequences, described in the following sections.
Divergent receptor pharmacology
The most consequential difference is what each peptide binds. Alpha-MSH's central His-Phe-Arg-Trp motif (residues 6–9) is the primary pharmacophore for engaging melanocortin receptors (MC1R, MC3R, MC4R and MC5R). Alpha-MSH activates these Gs-coupled receptors and raises intracellular cAMP, which feeds into downstream anti-inflammatory effects including suppression of NF-κB activity.
That core motif is absent from KPV. Binding studies generally describe KPV as having weak or negligible affinity for melanocortin receptors at concentrations that matter for the parent peptide, so its own anti-inflammatory research signal is usually interpreted as running through a largely receptor-independent, intracellular route. The literature is not unanimous on this point: some reports in specific cell types attribute part of KPV's activity to MC1R, so the receptor question should be treated as open and tested directly in the system under study. What is clearer is that the two peptides can converge on a similar NF-κB readout from different upstream starting points, which is exactly why researchers pair them in mechanistic-dissection designs rather than using one as a stand-in for the other.
Why the distinction matters for study design
Because the peptides diverge upstream of NF-κB, they are not equivalent even when an assay's readout looks similar. The practical consequences:
- Studies asking whether an effect is melanocortin-receptor-dependent need alpha-MSH, or a selective receptor agonist or antagonist, as the receptor-engaging arm, not KPV.
- Studies asking what remains of an anti-inflammatory signal when receptor engagement is excluded are where KPV is informative, since it helps isolate the receptor-independent component.
- Receptor knockout or antagonist experiments targeting MC1R, MC3R or MC4R are only interpretable with alpha-MSH or another confirmed receptor ligand as the active comparator.
- Both peptides should appear in the same experiment where possible, so that differences in readout cannot be attributed to differences in assay conditions.
A simple dissection design
| Arm | Question answered |
|---|---|
| Vehicle | Baseline inflammatory readout |
| Alpha-MSH | Response when melanocortin receptors are engaged |
| Alpha-MSH + receptor antagonist | How much of the response is receptor-dependent |
| KPV | Response that does not require the His-Phe-Arg-Trp core |
| KPV + receptor antagonist | Whether any KPV effect still depends on receptors in this cell type |
Delivery and stability considerations
Size drives a second practical difference. At 13 residues, alpha-MSH carries more protease-cleavage sites and is understood to be more susceptible to degradation in the gastrointestinal environment, and its size places it outside the substrate range of the PepT1 di- and tripeptide transporter. KPV's three-residue length and proline-containing backbone are reported to give comparative resistance to some proteases, and it falls within PepT1's substrate range, giving it a route into intestinal epithelial cells that alpha-MSH lacks. PepT1-mediated uptake of KPV in intestinal epithelial models was characterized by Dalmasso and colleagues (see references). This is one reason KPV appears more often in oral-delivery and intestinal-model research than alpha-MSH, independent of any difference in potency.
For the bench, the same size difference matters in other ways. A tripeptide has no aromatic residues, so detection by HPLC relies on the peptide bond near 214–220 nm, and a very small, polar peptide can elute near the void volume on reversed-phase columns unless the method is tuned. Identity is confirmed by mass spectrometry at about 342 Da. Those points are covered in KPV purity testing.
Where the research applications diverge
Alpha-MSH's literature is broad and includes areas where KPV has essentially no presence. Pigmentation and MC1R biology in melanocyte research is the clearest case: the eumelanin pathway depends on receptor activation that KPV does not meaningfully provide. Alpha-MSH also has a longer record in central-nervous-system inflammation research tied to MC4R expression. KPV's footprint is narrower, centered on intestinal and gut-barrier inflammation models, general in vitro anti-inflammatory signaling assays where its small size and stability are practical advantages, and hybrid constructs such as GHK-Cu combined with KPV. A broader comparison across related compounds is in KPV vs. other research peptides. Melanocortin analogs engineered for stronger receptor activity, such as those discussed in the melanotan II research overview, sit at the opposite end of the spectrum from KPV: they are designed around receptor engagement.
Summary comparison
| Feature | Alpha-MSH | KPV |
|---|---|---|
| Melanocortin receptor binding | Strong, multi-subtype | Weak to absent in most reports; cell-type-dependent claims exist |
| Primary anti-inflammatory route | Receptor-mediated (Gs/cAMP) | Largely receptor-independent, intracellular |
| Size | 13 residues, ~1,665 Da | 3 residues, ~342 Da |
| PepT1 substrate | No | Yes |
| Pigmentation research | Primary tool | Not applicable |
| Intestinal and oral-delivery models | Limited by size | Comparatively favored |
Sourcing and verification
Both V8 products below are lyophilized research material supplied with batch-specific documentation: the KPV research vial (5 mg, ≥98% HPLC purity listed) and the GHK-Cu + KPV blend (60 mg). Storage per the product pages is 2–8 °C, or −20 °C for the long term, protected from heat, moisture and light. Certificates are in the CoA library, and the badge on each product page shows whether the certificate for a given lot has been posted. For a 5 mg vial reconstituted in 1 mL the stock is 5 mg/mL; the peptide calculator handles other volumes. General sourcing criteria that apply to any peptide are in choosing a research peptide supplier, and KPV-specific sourcing is in where to buy KPV.
Research Use Only. For laboratory research use only; not for human consumption. This article is research education, not usage guidance.
Frequently asked questions
Is KPV the same as alpha-MSH?
No. KPV is a three-residue fragment (residues 11–13) of the 13-residue alpha-MSH. It lacks the His-Phe-Arg-Trp core that alpha-MSH uses to engage melanocortin receptors.
Does KPV activate melanocortin receptors?
Most binding reports describe weak or negligible affinity, and its anti-inflammatory signal is usually described as receptor-independent. Some reports in particular cell types suggest otherwise, so it should be tested in the system being used.
Why is KPV used in intestinal models?
It is a PepT1 substrate and is reported to resist some proteases, so it enters intestinal epithelial cells by a route that the larger alpha-MSH cannot use.
What is the mass of KPV and of alpha-MSH?
KPV is about 342 Da as the free tripeptide; alpha-MSH is about 1,665 Da. Mass spectrometry distinguishes them without difficulty.
Which peptide should I use to test receptor dependence?
Alpha-MSH, or a selective melanocortin agonist or antagonist. KPV is useful for examining what remains when the receptor-engaging motif is absent.
Can KPV substitute for alpha-MSH in pigmentation research?
No. Pigmentation depends on MC1R activation, which KPV does not meaningfully provide.
How is KPV detected by HPLC?
At 214–220 nm, since it has no aromatic residues. Its small size and polarity mean the method needs adequate retention.
How should KPV be stored?
Per the product page, at 2–8 °C or −20 °C long term, protected from heat, moisture and light.
References
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.
- Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews. 2008;29(5):581-602.
- V8 Peptides. KPV research overview.
- V8 Peptides. KPV vs. other research peptides.
- V8 Peptides. KPV research vial: product specifications.